Compare Cardinal Health Inc (CAH) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Linde PLC — how do they compare? Cardinal Health Inc trades at $227.64 (market cap $53.89B), while Linde PLC trades at $514.17 (market cap $241.59B). The key difference: Linde PLC is far larger — about 4.5× Cardinal Health Inc's market cap, and Linde PLC pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| CAH | LIN | |
|---|---|---|
Market Cap | $53.89B | $241.59B |
Sector | Health | Basic Materials |
52-Week High | $239.71 | $546.64 |
52-Week Low | $146.04 | $389.38 |
Enterprise Value | $58.87B | $263.95B |
Dividend Yield | 0.89% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Linde (LIN) trades at $524.06, down 1.08% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.33 exceeding estimates, and robust profitability margins including a 20.44% net income margin. Analyst consensus is strongly bullish with a $560 price target, supported by positive cash flow trends and a recent dividend declaration.
Outlook remains positive due to steady revenue growth, high return on equity of 18.49%, and institutional confidence. Risks include elevated valuation multiples like a P/E of 34.65 and rising debt-to-asset ratio, which could pressure shares if earnings growth slows. The stock presents a quality holding for growth-oriented investors mindful of valuation constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
